| Vol. 11.04 – 31 January, 2023 |
| |
|
|
| Investigators evaluated mutations in regions of the genome that were unlikely to undergo loss in a pan-cancer analysis across 31 tumor types and eight immunotherapy-treated cohorts of patients with non-small-cell lung cancer, melanoma, mesothelioma, and head and neck cancer. [Nature Medicine] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors performed a proof-of-concept single-arm phase II clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab, dabrafenib, and trametinib in 37 patients with BRAFV600E colorectal cancer. [Nature Medicine] |
|
|
|
| Researchers showed that a variable proportion of CD8+ T cells compartmentalized in the human liver co-stained for CD14 and other prototypic myeloid membrane proteins and were enriched in close proximity to CD14high myeloid cells in hepatic zone 2. [Nature] |
|
|
|
| This cohort study was performed in approximately 280 predominantly community-based US cancer clinics and included patients aged 18 years or older who had stage IIIB, IIIC, or IV non-small cell lung cancer. [JAMA Oncology] |
|
|
|
| In vitro recapitulation of TNF receptor 2 (TNFR2) signaling, by providing low-density membrane-bound precursor form of the cytokine TNF or a selective TNFR2 agonist, enhanced the generation of human T cell precursors. [Nature Immunology] |
|
|
|
| The authors used spherical nucleic acid nanoparticles to investigate how the spatial distribution and placement of two antigen classes affected antigen processing, cytokine production, and the induction of memory. [Nature Biomedical Engineering] |
|
|
|
| Scientists found an increase in tumor-infiltrating CD200+ cytotoxic T lymphocytes upon PD-1/PD-L1 blockade, with higher proportions of CD200+ T cells positively related to a favorable clinical outcome to anti–PD-1/PD-L1 therapy in three independent cohorts of patients with cancer. [Science Translational Medicine] |
|
|
|
| Lower USP18 expression correlated with better survival across human selected cancer types and delayed cancer progression in mouse models. [Nature Communications] |
|
|
|
| The authors collected serum samples from patients with gastric adenocarcinoma before, on, and after preoperative chemotherapy and studied their immune proteomics using an antibody-based proteomics panel. [Cell Reports Medicine] |
|
|
|
| Immune cells from tumor and peripheral blood were isolated from 42 patients with renal cell carcinoma and 5 patients with ovarian cancer. Researchers performed multicolor flow cytometry and RNA-sequencing to characterize the phenotypes and heterogeneity of intratumoral Tregs. [CLINICAL CANCER RESEARCH] |
| |
|
|
|
| The authors discuss progress in phosphatase drug discovery, with emphasis on the development of selective modulators that exhibit biological activity, and the roles and regulation of protein phosphatases in immune cells and their potential as targets for immuno-oncology and autoimmunity indications. [Nature Reviews Drug Discovery] |
|
|
|
| Scientists review recent advances in biomaterials-based strategies, focusing on targeting of lymphoid tissues, circulating leukocytes, tissue-resident immune cells, and immune cells at disease sites. [Nature Reviews Bioengineering] |
|
|
|
|
| Immusoft announced that the California Institute for Regenerative Medicine had awarded the company an $8M grant. [Immusoft] |
|
|
|
|
| March 28 – 29, 2023 London, England, United Kingdom |
|
|
|
|
|
| AstraZeneca – Cambridge, England, United Kingdom |
|
|
|
| Karolinksa Institutet – Solna, Sweden |
|
|
|
| Novartis – Munich, Germany |
|
|
|
| University of Oxford – Oxford, England, United Kingdom |
|
|
|
| Imperial College London – London, England, United Kingdom |
|
|
|
|